TransMedics Group, Inc. — Director's Dealing 2023

Feb 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2023-02-01

Reporting Person: Gordon Stephen (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-01	Common Stock	M	5000	$16.14	Acquired	10714	Direct
2023-02-01	Common Stock	S	5000	$62.64	Disposed	5714	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-01	Stock Option (Right to Buy)	$16.14	M	5000	Disposed	2030-02-27	Common Stock (5000)	Direct

Footnotes

F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.

F2: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 27, 2024.